Screening and monitoring approaches to optimise treatment in Ph+ leukaemias

Weekly carfilzomib, lenalidomide, and dexamethasone (krd) in relapsed or refractory multiple myeloma

Recent developments in immunotherapy in AML

A clinical trial of bb2121, a second generation CAR T cell for relapsed myeloma

The treating FL with rituximab added to chemoimmunotherapy

The iNNOVATE trial of rituximab with or without oral BTK-inhibitor ibrutinib to Waldenströms Macroglobulinemia

Highlights of the congress

A trial combining a novel antibody-drug conjugate with bendamustine and rituximab for patients whose disease has returned after initial treatment

Introduction to the consultation

Marginal zone lymphoma: Differentiation among pathologically challenging entities

Current state-of-the-art therapy for diffuse large B-cell lymphoma in 2018

A systematic review of predictors of venous thromboembolism in acute leukemia

A final analysis of treating CLL with obinutuzumab in place of rituximab alongside chlorambucil chemotherapy

Mapping the three-dimensional genome dynamics in normal and neoplastic b cells

Resolving hematopoiesis by fate mapping and polylox barcoding

Treatment options in second line and beyond: A case-based discussion